Abstract 49P
Background
Leptin is produced by adipose tissue of breast and is overexpressed in Breast cancer. Association of leptin gene (LEP) and leptin receptor gene (LEPR) polymorphisms with Breast cancer are inconsistent. Only a very few studies have examined this biochemical and genetic variables so we planned to investigate this association and its impact on leptin level and disease characteristics.
Methods
Study included 70 females (40 women with pathological prove of invasive Breast cancer patients and 30 controls). Staging was done according to the American Joint Committee on Cancer 8th edition. LEP and LEPR polymorphisms were estimated by real time PCR. Serum leptin was measured by ELISA.
Results
Both LEPR rs 1137101 and LEP rs 7799039 increase risk of breast cancer where GG genotype and G allele frequencies of LEPR rs 1137101 were significantly higher in patients than control [52.5% vs 16.7% and 68.8% vs 36.7%] (p = 0.002) and (p < 0.001) respectively. GG genotype increase risk of BC with [OR 9.1: 95% CI 2.30-35.94] while G allele predispose to disease with [OR 3.8: 95% CI 1.87 – 7.70]. Furthermore, LEP rs 7799039 A allele was markedly elevated in patients (61.2%) than healthy ones (43.3%) (p = 0.037) with [OR 2.06: 95% CI 1.05 – 4.08]. Leptin levels were markedly elevated than healthy ones (p < 0.001).
Conclusions
Results clarified interesting relation of circulating leptin level and LEP and LEPR polymorphisms with predicting Breast cancer that may be implicated in pathogenesis of disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract